
Cleerly is an Imaging & Diagnostics AI company founded in 2017 and based in Denver, United States. It has raised $372M in total funding, most recently a Series C in 2024.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Dec 4, 2024 | Series C | $106M | — | Insight Partners |
| Jul 25, 2022 | Series C | $223M | — | T. Rowe Price, Fidelity |
| Jun 21, 2021 | Series B | $43M | — | Vensana Capital |
No articles ingested yet for Cleerly. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
An AI-powered, FDA-cleared platform that analyzes coronary CT angiography (CCTA) scans to non-invasively quantify and characterize atherosclerotic plaque. It measures stenosis severity, plaque volume, and plaque composition (e.g., calcified, non-calcified, low-attenuation), generating a 3D model of the patient's coronary arteries. Designed for cardiologists and radiologists, Cleerly LABS provides a comprehensive, automated analysis that helps clinicians assess coronary artery disease with higher accuracy than traditional expert reading.
A lesion-specific ischemia assessment module that uses AI to determine the likelihood of ischemia (blood-flow obstruction) in individual coronary vessels. By combining plaque characterization data with patient-specific metrics, Cleerly ISCHEMIA estimates the hemodynamic significance of each stenosis, helping interventional cardiologists decide which lesions warrant revascularization. It aligns with professional guideline thresholds and offers a non-invasive alternative to invasive FFR measurements.
A longitudinal comparison tool that enables physicians to track changes in a patient's coronary plaque burden and composition over time across sequential CCTA scans. It overlays quantitative measurements from prior and current analyses to visualize disease progression or regression, supporting data-driven decisions about treatment efficacy and medication adjustments. This is especially valuable for managing patients with known coronary artery disease who require ongoing monitoring.
A workflow-support enhancement to Cleerly's AI-enabled quantitative CT platform, designed to streamline clinical reading workflows. PREVIEW provides pre-processed, prioritized views and automated case preparation so radiologists and cardiologists can review AI findings more efficiently. Launched in early 2026, it aims to reduce interpretation time while maintaining diagnostic confidence, making AI-powered plaque analysis more practical for high-volume clinical settings.








We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗